Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline

Abstract Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance cardiomyocyte performance. To assist translation to clinical practice we investigated OMs effect on explanted human failing hearts, specifically; contractile dynamics, interaction with the β1...

Full description

Bibliographic Details
Main Authors: Alexander Dashwood, Elizabeth Cheesman, Yee Weng Wong, Haris Haqqani, Nicole Beard, Karen Hay, Melanie Spratt, Wandy Chan, Peter Molenaar
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Pharmacology Research & Perspectives
Subjects:
Online Access:https://doi.org/10.1002/prp2.760
id doaj-b72fc90c024c4b669e467a550e0991fe
record_format Article
spelling doaj-b72fc90c024c4b669e467a550e0991fe2021-06-10T09:28:33ZengWileyPharmacology Research & Perspectives2052-17072021-05-0193n/an/a10.1002/prp2.760Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenalineAlexander Dashwood0Elizabeth Cheesman1Yee Weng Wong2Haris Haqqani3Nicole Beard4Karen Hay5Melanie Spratt6Wandy Chan7Peter Molenaar8Heart Lung Institute The Prince Charles Hospital Chermside QLD AustraliaCardio‐Vascular Molecular & Therapeutics Translational Research Group University of Queensland Brisbane QLD AustraliaHeart Lung Institute The Prince Charles Hospital Chermside QLD AustraliaHeart Lung Institute The Prince Charles Hospital Chermside QLD AustraliaQueensland University of Technology Brisbane AustraliaQIMR Berghofer Medical Research Institute Brisbane QLD AustraliaHeart Lung Institute The Prince Charles Hospital Chermside QLD AustraliaHeart Lung Institute The Prince Charles Hospital Chermside QLD AustraliaHeart Lung Institute The Prince Charles Hospital Chermside QLD AustraliaAbstract Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance cardiomyocyte performance. To assist translation to clinical practice we investigated OMs effect on explanted human failing hearts, specifically; contractile dynamics, interaction with the β1–adrenoceptor (AR) agonist (−)‐noradrenaline and spontaneous contractions. Left and right ventricular trabeculae from 13 explanted failing hearts, and trabeculae from 58 right atrial appendages of non‐failing hearts, were incubated with or without a single concentration of OM for 120 min. Time to peak force (TPF) and 50% relaxation (t50%) were recorded. In other experiments, trabeculae were observed for spontaneous contractions and cumulative concentration‐effect curves were established to (−)‐noradrenaline at β1‐ARs in the absence or presence of OM. OM prolonged TPF and t50% in ventricular trabeculae (600 nM, 2 µM, p < .001). OM had no significant inotropic effect but reduced time dependent deterioration in contractile strength compared to control (p < .001). OM did not affect the generation of spontaneous contractions. The potency of (−)‐noradrenaline (pEC50 6.05 ± 0.10), for inotropic effect, was unchanged in the presence of OM 600 nM or 2 µM. Co‐incubation with (−)‐noradrenaline reduced TPF and t50%, reversing the negative diastolic effects of OM. OM, at both 600 nM and 2 µM, preserved contractile force in left ventricular trabeculae, but imparted negative diastolic effects in trabeculae from human failing heart. (−)‐Noradrenaline reversed the negative diastolic effects, co‐administration may limit the titration of inotropes by reducing the threshold for ischemic side effects.https://doi.org/10.1002/prp2.760arrhythmiabeta‐adrenoceptorcontractilitydiastoleheart failureinotrope
collection DOAJ
language English
format Article
sources DOAJ
author Alexander Dashwood
Elizabeth Cheesman
Yee Weng Wong
Haris Haqqani
Nicole Beard
Karen Hay
Melanie Spratt
Wandy Chan
Peter Molenaar
spellingShingle Alexander Dashwood
Elizabeth Cheesman
Yee Weng Wong
Haris Haqqani
Nicole Beard
Karen Hay
Melanie Spratt
Wandy Chan
Peter Molenaar
Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
Pharmacology Research & Perspectives
arrhythmia
beta‐adrenoceptor
contractility
diastole
heart failure
inotrope
author_facet Alexander Dashwood
Elizabeth Cheesman
Yee Weng Wong
Haris Haqqani
Nicole Beard
Karen Hay
Melanie Spratt
Wandy Chan
Peter Molenaar
author_sort Alexander Dashwood
title Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
title_short Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
title_full Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
title_fullStr Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
title_full_unstemmed Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
title_sort effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
publisher Wiley
series Pharmacology Research & Perspectives
issn 2052-1707
publishDate 2021-05-01
description Abstract Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance cardiomyocyte performance. To assist translation to clinical practice we investigated OMs effect on explanted human failing hearts, specifically; contractile dynamics, interaction with the β1–adrenoceptor (AR) agonist (−)‐noradrenaline and spontaneous contractions. Left and right ventricular trabeculae from 13 explanted failing hearts, and trabeculae from 58 right atrial appendages of non‐failing hearts, were incubated with or without a single concentration of OM for 120 min. Time to peak force (TPF) and 50% relaxation (t50%) were recorded. In other experiments, trabeculae were observed for spontaneous contractions and cumulative concentration‐effect curves were established to (−)‐noradrenaline at β1‐ARs in the absence or presence of OM. OM prolonged TPF and t50% in ventricular trabeculae (600 nM, 2 µM, p < .001). OM had no significant inotropic effect but reduced time dependent deterioration in contractile strength compared to control (p < .001). OM did not affect the generation of spontaneous contractions. The potency of (−)‐noradrenaline (pEC50 6.05 ± 0.10), for inotropic effect, was unchanged in the presence of OM 600 nM or 2 µM. Co‐incubation with (−)‐noradrenaline reduced TPF and t50%, reversing the negative diastolic effects of OM. OM, at both 600 nM and 2 µM, preserved contractile force in left ventricular trabeculae, but imparted negative diastolic effects in trabeculae from human failing heart. (−)‐Noradrenaline reversed the negative diastolic effects, co‐administration may limit the titration of inotropes by reducing the threshold for ischemic side effects.
topic arrhythmia
beta‐adrenoceptor
contractility
diastole
heart failure
inotrope
url https://doi.org/10.1002/prp2.760
work_keys_str_mv AT alexanderdashwood effectsofomecamtivmecarbilonfailinghumanventriculartrabeculaeandinteractionwithnoradrenaline
AT elizabethcheesman effectsofomecamtivmecarbilonfailinghumanventriculartrabeculaeandinteractionwithnoradrenaline
AT yeewengwong effectsofomecamtivmecarbilonfailinghumanventriculartrabeculaeandinteractionwithnoradrenaline
AT harishaqqani effectsofomecamtivmecarbilonfailinghumanventriculartrabeculaeandinteractionwithnoradrenaline
AT nicolebeard effectsofomecamtivmecarbilonfailinghumanventriculartrabeculaeandinteractionwithnoradrenaline
AT karenhay effectsofomecamtivmecarbilonfailinghumanventriculartrabeculaeandinteractionwithnoradrenaline
AT melaniespratt effectsofomecamtivmecarbilonfailinghumanventriculartrabeculaeandinteractionwithnoradrenaline
AT wandychan effectsofomecamtivmecarbilonfailinghumanventriculartrabeculaeandinteractionwithnoradrenaline
AT petermolenaar effectsofomecamtivmecarbilonfailinghumanventriculartrabeculaeandinteractionwithnoradrenaline
_version_ 1721385293492256768